Exelixis Future Growth
Future criteria checks 4/6
Exelixis is forecast to grow earnings and revenue by 22.6% and 8.4% per annum respectively. EPS is expected to grow by 24% per annum. Return on equity is forecast to be 15.8% in 3 years.
Key information
22.6%
Earnings growth rate
24.0%
EPS growth rate
Biotechs earnings growth | 21.1% |
Revenue growth rate | 8.4% |
Future return on equity | 15.8% |
Analyst coverage | Good |
Last updated | 23 Apr 2024 |
Recent future growth updates
Recent updates
Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors
Apr 22Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024
Mar 28We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease
Feb 26Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles
Jan 17Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors
Dec 27An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued
May 30Exelixis initiated at outperform at JMP Securities on cash flow, Cabometyx franchise
Oct 18Exelixis: Efforts Continue To Diversify The Pipeline
Sep 15Exelixis, Teva fight over Cabometyx generic again
Sep 06Exelixis Needs To Move Away From Its Overdependence On Cabozantinib
Aug 03Exelixis again sues MSN Pharmaceuticals over Cabometyx generic
Jul 19Exelixis to pay Ryvu $3M upfront in license deal to develop targeted cancer drugs
Jul 07Exelixis: Becoming A Giant Pharma
May 18Exelixis: Beyond The Cabozantinib Franchise
Apr 21Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 2,332 | 598 | 551 | 768 | 14 |
12/31/2025 | 2,073 | 445 | 480 | 584 | 19 |
12/31/2024 | 1,908 | 379 | 373 | 412 | 21 |
12/31/2023 | 1,830 | 208 | 170 | 333 | N/A |
9/30/2023 | 1,774 | 92 | 134 | 396 | N/A |
6/30/2023 | 1,714 | 164 | 213 | 389 | N/A |
3/31/2023 | 1,664 | 154 | 118 | 299 | N/A |
12/31/2022 | 1,611 | 182 | 224 | 363 | N/A |
9/30/2022 | 1,638 | 308 | 343 | 385 | N/A |
6/30/2022 | 1,555 | 273 | 310 | 359 | N/A |
3/31/2022 | 1,521 | 298 | 453 | 509 | N/A |
12/31/2021 | 1,435 | 231 | 337 | 401 | N/A |
9/30/2021 | 1,254 | 164 | 275 | 338 | N/A |
6/30/2021 | 1,157 | 94 | 218 | 272 | N/A |
3/31/2021 | 1,031 | 65 | 152 | 192 | N/A |
12/31/2020 | 988 | 112 | 179 | 209 | N/A |
9/30/2020 | 958 | 152 | 310 | 334 | N/A |
6/30/2020 | 998 | 282 | 372 | 391 | N/A |
3/31/2020 | 979 | 294 | 408 | 421 | N/A |
12/31/2019 | 968 | 321 | 514 | 527 | N/A |
9/30/2019 | 956 | 612 | 465 | 474 | N/A |
6/30/2019 | 910 | 642 | 541 | 563 | N/A |
3/31/2019 | 856 | 650 | 473 | 506 | N/A |
12/31/2018 | 854 | 690 | 382 | 416 | N/A |
9/30/2018 | 745 | 368 | 316 | 364 | N/A |
6/30/2018 | 672 | 323 | 203 | 237 | N/A |
3/31/2018 | 585 | 253 | 145 | 169 | N/A |
12/31/2017 | 452 | 154 | 144 | 166 | N/A |
9/30/2017 | 410 | 150 | N/A | 197 | N/A |
6/30/2017 | 320 | 58 | N/A | 154 | N/A |
3/31/2017 | 257 | 6 | N/A | 122 | N/A |
12/31/2016 | 191 | -70 | N/A | 210 | N/A |
9/30/2016 | 124 | -147 | N/A | 90 | N/A |
6/30/2016 | 71 | -181 | N/A | 61 | N/A |
3/31/2016 | 43 | -186 | N/A | 60 | N/A |
12/31/2015 | 37 | -162 | N/A | -141 | N/A |
9/30/2015 | 35 | -178 | N/A | -156 | N/A |
6/30/2015 | 31 | -195 | N/A | -180 | N/A |
3/31/2015 | 30 | -229 | N/A | -208 | N/A |
12/31/2014 | 25 | -261 | N/A | -235 | N/A |
9/30/2014 | 22 | -281 | N/A | -233 | N/A |
6/30/2014 | 21 | -286 | N/A | -232 | N/A |
3/31/2014 | 27 | -275 | N/A | -216 | N/A |
12/31/2013 | 31 | -245 | N/A | -199 | N/A |
9/30/2013 | 35 | -226 | N/A | -190 | N/A |
6/30/2013 | 43 | -192 | N/A | -167 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EXEL's forecast earnings growth (22.6% per year) is above the savings rate (2.3%).
Earnings vs Market: EXEL's earnings (22.6% per year) are forecast to grow faster than the US market (14.4% per year).
High Growth Earnings: EXEL's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: EXEL's revenue (8.4% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: EXEL's revenue (8.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EXEL's Return on Equity is forecast to be low in 3 years time (15.8%).